TORONTO, Sept. 26, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO)
has announced an expansion of their strategic alliance with HealthSaaS,
Inc to add the Cloud DxTM solution and non-invasive blood glucose measurements to the HealthSaaS
Connected Outcomes Framework®.
Frank Ille, CEO, HealthSaaS stated "Our partnership will allow Connected
Outcomes Framework® services to deliver a broad range of data and
analytics that will measurably improve the quality of life for patients
and lower costs to providers and payers."
The CloudDxTM solution and UFIT® device integrated with HealthSaaS Connected Outcomes
Framework® will deliver sophisticated, reliable personal health
monitoring that augments patient and disease management. The alliance
will provide accurate, secure vitals monitoring, including blood
pressure and glucose analysis with integrated real-time reporting to
the complete circle of care (patient, family, nurses, physicians,
healthcare provider, and payer).
Dr. Scott Jenkins, CEO of BioSign stated "Our New Cloud DxTM solution and non-invasive blood glucose data integrated with HealthSaaS
Connected Outcomes Framework® services is a significant step forward to
facilitating seamless collaboration and providing quality metrics for
the healthcare ecosystem. By working together, we plan to lower the
costs for payers and at the same time improve the quality of life for
patients with diabetes, hypertension, and cardio-vascular diseases."
About HealthSaaS, Inc.
At HealthSaaS we have a genuine curiosity that inspires us to think
differently. We exist to challenge the status quo and are driven by a
sense of purpose to empower every segment of the healthcare system. Our
vision allows us to create solutions that enhance provider
efficiencies, track outcomes and improve the quality of life for
patients throughout the continuum of care. For more information visit: www.healthsaas.net
About Biosign Technologies Inc
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems
through its Cloud DxTM branded solution. Cloud DxTM applications include intelligent systems for non-invasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. Biosign technology combines measurement, analysis, and
tools for disease and patient management to support global vital health
monitoring. The UFIT® medical device delivers quality data collection
and analytics for clinical diagnostics, self-care, wellness, disease
state evaluation and management, and remote patient monitoring. For
more information visit: www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
Biosign/Cloud Dx Contact: